Macrophage inflammatory protein (MIP)-1a, MIP-1b, and RANTES production were measured by ELISA in whole blood that had been stimulated for 4.5 h with phytohemagglutinin. The blood was from 90 healthy human immunodeficiency virus (HIV) -negative controls and from 245 HIVinfected subjects who were followed for £4.5 years. HIV-infected persons without AIDS had increased levels of MIP-1a, MIP-1b, and RANTES (P õ .01) compared with levels in controls. Subjects with AIDS, compared with controls, had decreased production levels of MIP-1b (P õ .0001) and similar levels of MIP-1a and RANTES. A high level of MIP-1b production was associated with a decreased risk of progressing to AIDS or death, as determined by univariate analysis (P õ .01) and adjusted for CD4 cell count and age (P Å .07, P Å .06, respectively). The findings suggest that the production level of b-chemokine changes during HIV infection and that a high level of b-chemokine production in peripheral blood lymphocytes may be associated with less rapid disease progression in HIV infection.
The b-chemokines macrophage inflammatory protein Serum levels of MIP-1a, MIP-1b, and RANTES in nonprogressing HIV-infected persons have been shown to be similar (MIP)-1a, MIP-1b, and RANTES inhibit infection of different cell lines by macrophagetropic human immunodeficiency virus or lower than those in persons with progressing HIV infection [14, 15] . b-chemokine production by persons in different stages (HIV) isolates [1 -4] . The C-C-chemokine receptor (CKR)-5 is a coreceptor for several macrophagetropic HIV isolates of HIV infection has been compared only among a selected group of subjects who were not followed prospectively after [4 -6] , and MIP-1a, MIP-1b, and RANTES seem to inhibit HIV replication by interfering with the binding between gp120 the b-chemokine measurement [16, 17] . These studies did not reveal a clear association of either higher or lower b-chemokine and CKR-5 [4, 7 -9] . The importance of CKR-5 -HIV interactions has been further strengthened by several reports of resisproduction with disease progression. Thus, even though the b-chemokines and their receptors tance to HIV infection in persons with mutant alleles of the CKR-5 receptor [10 -12] and by reports of delayed progression seem to be very important in the pathogenesis of HIV infection, the exact role of b-chemokine levels in disease progression to AIDS in individuals heterozygous for CKR-5 [12] .
However, it has also been reported that CD4 / cells can remains unknown. Herein, we examine the production of MIP-1a, MIP-1b, and RANTES in a large prospectively folremain resistant to infection by macrophagetropic HIV isolates in the presence of anti -b-chemokine antibodies [4] . In addilowed cohort of HIV-infected persons. The use of a large study group makes it possible to examine the level of b-chemokine tion, an unchanged [4] or even increased [13] rate of infection by HIV in primary monocytes in the presence of MIP-1a, production at different stages of HIV infection, the relationship between b-chemokine levels and concentrations of cells capa-MIP-1b, and RANTES has been described. ble of producing b-chemokines, and the prognostic value of b-chemokine levels in the prediction of disease progression. Statistical analysis. Log-transformed levels of MIP-1a, (range, 0.02-4.54) from the date of enrollment. Four subjects were excluded from survival analysis due to missing CD4 lymphocyte MIP-1b, and RANTES production among controls, HIV-infected subjects without AIDS, and HIV-infected subjects with AIDS were counts at enrollment. To reduce loss to follow-up, we collected data from the National Registry System (NRS) for the HIV-infected compared by one-way analysis of variance and analysis of covariance (ANCOVA), adjusting for the number of lymphocytes. Mean individuals who moved during the follow-up period. Complete data were collected for all individuals attending other hospitals in values and 95% confidence intervals (95% CIs) were calculated (unadjusted and adjusted for the lymphocyte concentration) for Denmark. Seven persons were censored before or during followup because of emigration, and 1 person was registered in NRS as MIP-1a, MIP-1b, and RANTES production in each of the 3 groups of subjects. ''disappeared'' during follow-up. CD4 lymphocytes were counted at enrollment and at about 4, 8, 12, 24 , and 36 months after enroll-
The relationship between b-chemokine production and the numbers of CD4
/ and CD8 / lymphocytes, NK cells, and monocytes ment. The median number of CD4 measurements was 5 (range, 1-6). During the follow-up period, 113 subjects died and 56 develand age at enrollment was analyzed by linear regression analysis with all variables on the log scale. Each independent variable was oped AIDS.
Supernatants. Whole blood supernatants were generated by tested for interaction with HIV serostatus; if an interaction was found, separate slopes were calculated for controls and for HIVincubating 2 mL of anticoagulated blood (10 mL of heparin 5000 IU/mL; SAD, Copenhagen) with 10 mg of PHA (PHA-P; Difco, infected subjects. Analysis was performed both univariately and in a multivariate model adjusting for the effect of the other variDetroit) for 4.5 h at 37ЊC in 5% CO 2 . After being centrifuged at 5ЊC, the supernatants were stored at 080ЊC until thawed and then ables. The concentration of b 2 -microglobulin and the number of platelets were not included as independent variables in multiple analyzed. Previously performed kinetic analyses had shown that 4.5 h of PHA stimulation was sufficient to induce high levels of linear regression analysis because they were measured only in HIV-infected subjects. The relationship between the log-trans-MIP-1a, MIP-1b, and RANTES. The short, 4.5-h PHA stimulation was used in this study to reduce the influence of proteolytic degraformed values of the three b-chemokines and the concentration of b 2 -microglobulin or the number of platelets was analyzed by use dation and cellular proliferation on the b-chemokine levels.
Cytokine detection. MIP-1a, MIP-1b, and RANTES in whole of Pearson's correlation analysis in the HIV-infected subjects. Survival analysis was done considering three main end points: blood culture supernatants were measured in duplicate by commercially available ELISA kits (R&D Systems, Minneapolis), aca CD4 cell count of õ100 cells/mm 3 (only subjects with a first CD4 cell count ú100 cells/mm 3 ), a clinical AIDS diagnosis defined cording to the manufacturer's instructions. The ELISA kits all had detection limits of õ6 pg/mL and an intra-and interassay coeffiaccording to the 1993 Centers for Disease Control and Prevention definition (only subjects without AIDS at enrollment), and death cient of variation below 10%.
Clinical chemical tests. Concentrations of lymphocytes, (AIDS related)
. The progression to each end point was evaluated in the Cox's proportional-hazard model, with the production of monocytes, neutrophils, and platelets (platelets only in HIVinfected persons) were measured by use of a cell counter (Techeither MIP-1a, MIP-1b, or RANTES and age and CD4 cell count at enrollment included as covariates. Despite the fact that the nicon H.1; Miles, Tarrytown, NY). Serum b 2 -microglobulin concentrations were measured in HIV-infected subjects by use of a CD16 / /CD56 / NK cell count was a potential confounder, it was not included in the final multivariate Cox models because it was quantitative competitive enzyme (Pharmacia Diagnostics, Piscataway, NJ). The concentration of blood mononuclear cells was calcunot univariately associated with any of the outcomes of the survival analysis. lated as the sum of lymphocyte and monocyte concentrations.
Flow cytometry and monoclonal antibodies. To determine the number of different cytokine-producing cells, flow cytometry analysis was done as previously described [18] . For purposes of this production in AIDS-free subjects and controls (figure 1). Subin controls (R Å .74, P õ .0001). The production of MIP-1a and MIP-1b was correlated to RANTES production in controls jects with AIDS had unchanged levels of RANTES compared with levels in HIV-infected subjects without AIDS and in-(R Å .34, P Å .0001; R Å .33, P Å .0001, respectively) but not in HIV-infected subjects (R Å 0.02, P Å .7; R Å .01, creased lymphocyte-adjusted RANTES levels compared with levels in controls ( figure 1) . P Å .9, respectively).
In the HIV-infected subjects, RANTES production but not Linear regression analysis. As shown in table 1, the production of all three b-chemokines was positively correlated to MIP-1a and MIP-1b production correlated to the number of platelets (R Å .39, P õ .0001; R Å .06, P Å .4; R Å .10, the number of NK cells in both HIV-infected and control subjects. The correlation was still significant after adjusting for P Å .1, respectively), whereas MIP-1a and MIP-1b production but not RANTES production correlated negatively to the age and concentrations of CD4 / T cells, CD8 / T cells, and CD14
/ monocytes in multiple linear regression analysis. The b 2 -microglobulin concentration (R Å 0.27, P õ .0001; R Å 0.35, P õ .0001; R Å 0.06, P Å .4, respectively). The production of MIP-1a and MIP-1b but not RANTES was also correlated to the number of CD4 / cells in both HIV-infected correlations to the concentrations of platelets and b 2 -microglobulin were still significant after adjusting for the effect of and control subjects in univariate and multiple linear regression analysis (table 1) . Of interest, the production of MIP-1a and lymphocyte subsets and age in multiple linear regression analysis (data not shown). MIP-1b was negatively correlated to age in HIV-infected subjects but not in controls (table 1). The negative correlation
Expected changes in b-chemokine production. The median numbers of CD4 / and NK cells and the median age for the between age on one side and MIP-1a and MIP-1b production on the other side also remained significant in the multiple HIV-infected subjects with and without AIDS were used to calculate the expected changes in production of MIP-1a, linear regression model (table 1) . RANTES production was not correlated to age in either group (table 1). The numbers of MIP-1b, and RANTES by multiplying the values with the respective coefficients from multiple linear regression analysis. CD8 / T cells and CD14 / monocytes were not correlated to the production of any of the three b-chemokines in HIV-infected or
The changes in the median numbers of CD4 / and NK cells and the median age predicted a ú50% reduction in the produccontrol subjects (data not shown).
The production of MIP-1a and MIP-1b was highly corretion of MIP-1a and MIP-1b but only an 8% reduction in the production of RANTES in subjects with AIDS compared with lated in the HIV-infected subjects (R Å .77, P õ .0001) and / 9d3f$$fe08
12-23-97 07:54:02 jinfa UC: J Infect MIP-1b was still associated with a decreased risk of progressing to AIDS or death (P Å .07 for CD4 cell count; P Å .06 for age; table 2). Production of RANTES did not predict progression to any of the three end points in univariate or multivariate analysis (table 2) . In Cox's regression analysis, older age and lower CD4 / lymphocyte count were univariately associated with a higher RANTES. From the multiple linear regression analysis, the large difference in the production of MIP-1a and MIP-1b AIDS compared with healthy controls could not be explained also have to examine if PHA-stimulated b-chemokine production correlates to in vivo levels of b-chemokines. by these factors because the HIV-infected subjects compared with controls had lower or unchanged numbers of the lymphoProtective role of MIP-1b in disease progression. Survival analysis showed that high levels of MIP-1b and, to a lesser cyte subsets that were positively correlated with b-chemokine production [18] . Furthermore, since production of MIP-1a and extent, MIP-1a production were associated with a decreased risk of disease progression. The level of RANTES production MIP-1b correlated negatively to the b 2 -microglobulin concentration, the high b-chemokine production in early HIV infection was not associated with the risk of progression to any of the three end points considered in this study. The levels of was not simply caused by a general immune activation.
RANTES production was not correlated to the concentra-MIP-1b and RANTES measured in this study corresponded to concentrations that have been documented to inhibit HIV tions of the leukocyte subsets included in the regression analysis; however, it was closely correlated to the number of platereplication, whereas the level of MIP-1a production was below the concentration at which inhibition of HIV replication exists lets. It is therefore likely that the RANTES measured in this study was mainly released by platelets in accordance with pre- [1] . Thus, the differential effect of MIP-1b and RANTES on disease progression in this study cannot be ascribed to differvious reports of activated platelets as a major source of RANTES production [19 -22] . Any differences in RANTES ences in levels of HIV replication inhibition induced by the two chemokines. However, since the MIP-1b and MIP-1a meaproduction in the lymphocyte subset between groups of HIVinfected and control subjects are therefore likely to be masked sured in this study seemed to reflect production by lymphocytes and the measured RANTES seemed to be released by platelets, by high levels of RANTES released by the population of platelets. Since MIP-1a and MIP-1b did not correlate to the platelet the differential effect on disease progression may be explained by the differences in the way the chemokine release was mediconcentration, platelets did not seem to contribute significantly to the MIP-1a and MIP-1b levels, which is in accordance with
ated.
An alternative explanation to the observed differences in the previous reports [21, 22] .
Some studies have reported serum levels of RANTES at level of protection against HIV disease progression provided by three b-chemokines may be related to the differences in the levels comparable to those in the PHA-stimulated whole blood in our current study [14, 15] . These studies concluded that relative affinity of the chemokines to the different b-chemokine receptors. RANTES is known to bind to CKR-1, CKR-3, no differences in serum RANTES levels exist between HIVinfected persons with progressive infection, HIV-infected per-CKR-4, and CKR-5, whereas MIP-1b only binds to CKR-5 [23] . Therefore MIP-1b has a narrower range of immunologic sons with nonprogressive infection, and healthy HIV-negative controls. However, these serum levels of RANTES are likely activities than does MIP-1a or RANTES [24] . Thus, with MIP1b, a high degree of HIV inhibition may be achieved with a to result from in vitro release of RANTES by platelets, and they may therefore not represent the circulating levels of RANTES.
relatively limited immunologic activation. This study did not examine the mechanism by which The finding of a strong negative correlation between age and production of MIP-1a and MIP-1b in HIV-infected persons b-chemokine production was related to differences in disease progression. However, the levels of MIP-1b and MIP-1a were but no correlation in healthy controls is an intriguing feature that cannot be explained by the present data.
highly correlated to the production of IFN-g (Ullum et al., unpublished data). Thus, the relationship between high levels The lack of correlation between the number of CD8 / cells and b-chemokine production does not exclude the possibility of MIP-1b and a decreased risk of disease progression in HIV infection may not be caused by a direct inhibition of HIV that the CD8 / cells may have contributed to the released MIP-1a, MIP-1b, and RANTES. However, it does indicate replication but may reflect a more general protective role of Th1 cytokines on HIV infection [25] . In conclusion, our findthat changes in the number of CD8 / cells did not explain variation in the levels of the three b-chemokines. Thus, if bings suggest that a high b-chemokine production in peripheral blood lymphocytes is protective against disease progression in chemokine release in CD8 / cells was regulated by cytokine production in the CD4
/ and NK cells, the b-chemokine produc-HIV infection, but they do not reveal how this protection is mediated. tion would not have to correlate to the number of CD8 / cells. The present methodology does not allow for analysis of the exact cellular sources of b-chemokine liberation. The b-
